LaunchTrends®: Lemtrada (US) is a four-wave syndicated report series that specifically tracks the introduction of Lemtrada, a potent, intravenous disease-modifying therapy (DMT) approved to treat relapsing forms of multiple sclerosis (MS). This report series is based on primary research data collected at one month, three months, six months, and one year post-commercial availability of Lemtrada. Along with awareness and sources of familiarity, the reports assess U.S. neurologists’ trial, adoption, and use of Lemtrada, including anticipated future trends. The reports also provide information on product perception, satisfaction, obstacles to use, drivers of prescribing, patient types, displacement of competitors, Genzyme’s promotional efforts, and benchmarking against other previously launched MS agents.

Questions Answered:  

  • Genzyme launched Lemtrada in the U.S. market as a treatment for relapsing forms of MS in December 2014. What is neurologists’ level of awareness of and familiarity with Lemtrada over the course of the following year?
  • Lemtrada enters an increasingly crowded MS therapy market; there are ten branded DMTs, four of which launched in the past five years. What are the perceived clinical advantages and disadvantages of Lemtrada compared with other marketed MS agents? How are the trial and adoption of Lemtrada tracking compared with other recent product launches for MS?
  •  Because of its safety profile, Lemtrada’s U.S. label recommends that it should generally be reserved for later-line treatment of relapsing forms of MS. Where do neurologists expect Lemtrada to fit in the MS treatment algorithm? What are the current prescribing trends among DMTs, and how do neurologists anticipate they will change over the next six months?
  •  Lemtrada is Sanofi/Genzyme’s second entrant into the MS market, following the companies’ 2012 launch of Aubagio. What promotional messages and activities is Genzyme using to support Lemtrada’s launch?


Markets covered: United States.

Primary research: 74 neurologists surveyed per report Wave; 10 qualitative interviews with a subset of survey respondents.

Indication coverage: Relapsing-remitting MS.

Table of contents

  • Multiple Sclerosis - Emerging Therapies - Lemtrada Launch Tracking Wave 4 (US)
    • Key Findings
      • Awareness and Perceptions of Lemtrada
      • Current Lemtrada Trial and Use
      • Lemtrada Positioning in the Competitive Landscape
      • Anticipated Lemtrada Trial and Use
    • Benchmarking Lemtrada Launch Success vs. MS Analogs
      • Benchmarking Metrics
    • Prescriber and Nonprescriber Profiles
      • Lemtrada Awareness and Perceptions
        • Unaided and Aided Awareness of Lemtrada
          • Aided Awareness of Lemtrada
        • Familiarity with Lemtrada
          • Familiarity with Lemtrada
          • Awareness of Lemtrada Indication*
          • Awareness of Lemtrada Administration*
          • Awareness of Lemtrada Dosing Interval*
        • Sources of Familiarity with Lemtrada
          • Initial Reaction to and Interest in Lemtrada
            • Lemtrada Product Profile
            • Initial Reaction to Lemtrada
            • Interest Level in Lemtrada
          • Impressions of Lemtrada
            • Clinical Interchangeability of Lemtrada and DMT Brands
            • Awareness of Lemtrada Information
            • Information in Profile of Which Lemtrada-Aware Neurologists Were Unaware
            • Open-End Responses
            • Statement Agreement Regarding Lemtrada
            • Uniqueness of Lemtrada vs. Currently Available Treatments
            • Lemtrada Risk-Benefit Profile Balance
            • Unaided Lemtrada Advantages
            • Open-End Responses
            • Unaided Lemtrada Disadvantages
            • Open-End Responses
            • Qualitative Interview Follow-Ups
          • Prescriber and Nonprescriber Profiles
          • Lemtrada Trial and Use
            • Willingness to Prescribe Lemtrada
              • Lemtrada Trial
              • Willingness to Prescribe Lemtrada
              • Qualitative Interview Follow-Ups
            • Number of Patients Currently Receiving Lemtrada
              • Qualitative quote
              • Percentage of Physicians Receiving Patient Inquiries for Lemtrada in the Past Month
              • Action Based on Specific Lemtrada Patient Requests
              • Qualitative Interview Follow-Ups
              • Qualitative Interview Follow-Ups
              • Mean Lemtrada Patient Volume Among Lemtrada Prescribers
              • Circumstances of Initial Lemtrada Prescriptions*
              • Current Lemtrada Status
              • Lemtrada Prescribing by Disease Classification Among Current Prescribers
              • Lemtrada Patient Origination
              • Patients Switched to Lemtrada (Percentage of Patients)
              • Qualitative Interview Follow-Ups
              • Number of DMTs Used Prior to Lemtrada
              • Qualitative Quotes
              • Course of Lemtrada Treatment Among Current Prescribers
              • Qualitative Quotes
              • Severity of Infusion-Associated Reactions to Lemtrada
              • Percentage of Patients on Lemtrada Seen for Follow-Up
              • Response to Lemtrada Treatment
            • Reasons for Not Yet Prescribing Lemtrada
              • Reason for Not Yet Initiating Patients on Lemtrada
              • Anticipated Lemtrada Prescribing Time Frame Among Nonprescribers
            • Anticipated Lemtrada Use
              • Anticipated RR-MS DMT Treatment Rate: Next Six Months
              • Lemtrada Prescriber Base: Current, Next Six Months, and Ever
              • Anticipated Change in Brand Allocation Among DMT-Treated RR-MS Patients
              • Potential Peak Share for Lemtrada
              • Potential Peak Share for Lemtrada
              • Characteristics of Lemtrada Candidates
              • Characteristics of Lemtrada Candidates
              • DMT That Lemtrada Will Likely Replace
              • Qualitative Quotes
              • Three Main Aided Obstacles to Lemtrada Prescribing for RR-MS Patients
              • Qualitative Interview Follow-Ups
            • Lemtrada Performance on Key Attributes
              • Lemtrada Performance Ratings and DMT Choice Attribute Importance Ratings
              • Lemtrada Performance Ratings and DMT Choice Attribute Importance Ratings
              • Overall Attribute IMP Ranking
              • Select Reasons for High Satisfaction Rating (8-10) (n = 20)
              • Overall Lemtrada Satisfaction
              • DMT MOST Associated with Attribute (Percentage of Neurologists)
              • DMT LEAST Associated with Attribute (Percentage of Neurologists)
              • Lemtrada Chosen as DMT MOST Associated with the Following Attributes (Percentage of Neurologists)
              • Lemtrada Chosen as DMT LEAST Associated with the Following Attributes (Percentage of Neurologists)
          • Effectiveness of Face-to-Face Detailing for Lemtrada
            • Lemtrada Sales Representative Frequency and Reach
              • DMT Detailing Frequency Among All Surveyed Neurologists
              • Qualitative Interview Follow-Ups
            • Satisfaction with Lemtrada Sales Representative
              • Qualitative Quotes
              • Satisfaction Rating for Lemtrada Sales Representative Quality Attributes
              • Unaided Advice for Lemtrada Promotion
              • Open-End Responses
            • Lemtrada Message Recall
              • Qualitative Quotes
              • Main Unaided Message Discussed with Lemtrada Sales Representatives
              • Topics Discussed with the Lemtrada Sales Representative*
              • Topics Discussed with the Lemtrada Sales Representative*
          • Methodology
            • Significance Testing in This Study
          • Appendix
            • Primary Market Research
              • Years in Practice Postresidency (Percentage of Neurologists)
              • U.S. Region of Practice (Percentage of Neurologists)
              • Practice Location (Percentage of Neurologists)
              • Practice Setting (Percentage of Neurologists)
              • Practice Demographic Differences
              • MS Patient Volume Under Personal Management in Past Year
              • Patient Allocation by MS Disease Classification
              • Lemtrada REMS Program Enrollment Status
              • Enrollment Process Rating
              • Qualitative quote
            • Additional Information
              • Impact of Lemtrada Attributes on Willingness to Prescribe: Wave over Wave
              • Potential Issues Affecting Willingness to Prescribe Lemtrada: Wave over Wave
              • Lemtrada Statement Agreement: Wave over Wave
              • Respondent Feedback
              • DMTs Indicated for the Treatment of Relapsing Forms of MS in the United States
              • MS Market News: Lemtrada Launch
              • Report Abbreviations
              • Objectives
              • Likely Actions Taken Upon Lemtrada Request
              • Likely Scenario Upon Referral
              • Changes in Management/Treatment of MS Patients in Past Six Months*
              • Qualitative Interview Follow-Ups
              • DMT Treatment Rate Among RR-MS Patients
              • Current Brand Share Among DMT-Treated RR-MS Patients (Percentage of DMT-Treated RR-MS Patients)
              • Last Ten New DMT Prescriptions for RR-MS Patients (Percentage of DMT Prescriptions)
              • Last Ten Switch DMT Prescriptions for RR-MS Patients (Percentage of DMT Prescriptions)
              • Perception of Managed Care Approval Process Among Lemtrada Prescribers
              • Qualitative Quotes
              • Reasons Why the Managed Care Approval Process Was Difficult and Time Consuming (n=5)
              • Managed Care Requirements for Prescribing Lemtrada*
              • Most Common DMT Failures Requested by MCOs
              • Percentage of Lemtrada Prescriptions Denied to…
              • Value of Genzyme’s Support Activities for Lemtrada

        Author(s): John Crowley

        John leads DRG’s Infectious, Niche, & Rare Diseases team and manages the market research portfolio across niche and rare diseases, anti-infectives, and vaccines. Prior to his current role, he was a Director on the team overseeing syndicated and custom work on niche and rare disease markets, as well as atopic dermatitis content in DRG’s Dermatology portfolio. He also served as a DRG analyst in the neurology space, focused mainly on the multiple sclerosis market. John holds a Ph.D. from the University of Massachusetts Medical School and a Bachelor’s degree from Worcester Polytechnic Institute.

        Related Reports

        Multiple Sclerosis - Landscape & Forecast - Disease Landscape & Forecast

        The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will c...

        View Details

        Multiple Sclerosis | Disease Landscape and Forecast | G7 | 2020

        The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will continue to fragment as new entrants drive further shifts in a complicated treatment alg...

        View Details

        Multiple Sclerosis - Current Treatment - Detailed, Expanded Analysis (US)

        Three disease-modifying therapies (DMTs)—EMD Serono’s Mavenclad, Novartis’s Mayzent, and Biogen’s Vumerity—joined the crowded U.S. multiple sclerosis (MS) market just...

        View Details

        Multiple Sclerosis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis Multiple Sclerosis 2020 – Main Report Dashboard (US)

        With more than a dozen immunomodulatory disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS) and more in the pipeline, the treatment journey for U.S. MS patients continues...

        View Details